
Please try another search
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis, as well as in Phase III clinical trials for the treatment of non-small lung cancer. The company was founded in 2003 and is headquartered in Miami, Florida.
Name | Age | Since | Title |
---|---|---|---|
Yu Xia | 56 | 2023 | Director |
Mahkam Zanganeh | 54 | 2020 | Co-CEO, President & Director |
Robert F. G. Booth | 70 | 2022 | Independent Director |
Kenneth A. Clark | 66 | 2021 | Lead Independent Director |
Robert W. Duggan | 81 | 2019 | Co-CEO & Executive Chairman |
Marcel van den Heuvel | - | - | Member of Scientific Advisory Board |
Derek Stemple | - | - | Member of Scientific Advisory board |
William Graham Richards | 85 | - | Member of Scientific Advisory board |
Jean-Paul Vincent | - | - | Member of Scientific Advisory board |
Roger Patient | - | - | Member of Scientific Advisory Board |
Bob Sim | - | - | Member of Scientific Advisory board |
Francesco Muntoni | - | - | Member of Scientific Advisory Board |
Mostafa Ronaghi | 56 | 2024 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review